Navigation Links
Alexza Presents Staccato® Loxapine Responder Analyses in Agitated Adult Patients with Schizophrenia or Bipolar Disease at the 2011 USPMHC Annual Conference

MOUNTAIN VIEW, Calif., Nov. 8, 2011 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq:  ALXA) today announced that it is presenting at the 24th Annual U.S. Psychiatric and Mental Health Congress, being held November 7 - 10, 2011.  The abstract and poster presentation, entitled "Treating Agitation with Inhaled Loxapine (AZ-004): Responder Analyses in Patients with Schizophrenia or Bipolar Disorder", is being presented today by Dr. James V. Cassella, Alexza's Senior Vice President of Research and Development.  Alexza has previously reported and presented the primary findings of its two Phase 3 clinical trials with Staccato loxapine.  In this presentation, Alexza is presenting additional analyses of these data, using two different responder methodologies.


The efficacy of Staccato loxapine in treating agitation was measured using the PANSS-Excited Component (PEC) and Clinical Global Impression - Improvement (CGI-I) scales in two Phase 3 randomized, double-blind, placebo-controlled trials in agitated patients with schizophrenia (n=344) or bipolar I disorder (n=314).  At the beginning of the treatment period, patients received a single inhalation of either 0mg (placebo), 5mg or 10mg of Staccato loxapine.  The primary endpoint was successfully achieved in both studies and has been previously reported and published.  As a further efficacy assessment, two responder analyses, PEC40 and CGI-Improvement, were conducted with responders defined as: (1) patients with a >40% decrease from baseline in the total PEC score (starting at 10 minutes post-dose); and (2) patients rated as "much improved" or "very much improved" on the CGI-I scale (assessed at 2 hours post-dose).  Responder analyses are important as they are a method to determine the magnitude of clinical relevance of patient response to a treatment.

PEC40 Responders Analysis

In agitated patients with schizophrenia or bipolar disorder, the number of PEC40 responders was statistically significantly greater at all time points for patients treated with either dose of Staccato loxapine, compared to patients who received Staccato placebo.  Importantly, significant differences from placebo were noted at the first assessment time of 10 minutes post-dose for both dose groups and in both patient groups.  The results for the PEC40 Responders analysis are summarized below.Staccato Loxapine PEC40 Responder AnalysisSchizophrenia Patients(% with >40% decrease from baseline PEC score)5mg

10mgTime Point


Staccato Loxapine

Staccato Loxapine10 minutes



18.8%20 minutes



42.9%30 minutes



57.1%45 minutes



70.5%60 minutes



71.4%90 minutes



74.1%120 minutes



69.6%Staccato Loxapine PEC40 Responder AnalysisBipolar Disorder Patients(% with >40% decrease from baseline PEC score)5mg

10mgTime Point


Staccato Loxapine

Staccato Loxapine10 minutes



21.9%20 minutes



49.5%30 minutes



61.9%45 minutes



70.5%60 minutes



72.4%90 minutes



72.4%120 minutes



73.3%CGI-I Responders Analysis

In patients with schizophrenia, 57.4% of the 5mg patients and 67.0% of the 10mg patients treated with Staccato loxapine were CGI-I responders, compared with 35.7% of placebo patients.  In patients with bipolar disorder, 66.3% of the 5mg patients and 74.3% of the 10mg patients treated with Staccato loxapine were CGI-I responders, compared with 27.6% of placebo patients.  In both patient populations, the CGI-I responders were statistically significantly greater for patients treated with either dose of Staccato loxapine, compared to patients who received Staccato placebo.  The results for the CGI-I Responders analysis are summarized below.

Staccato Loxapine CGI-I Responder Analysis2-Hour CGI-Improvement(% of Patients Rated as "Much Improved" or "Very Much Improved")Schizophrenia

Bipolar DisorderStaccato Loxapine Dose Group








28%About Alexza Pharmaceuticals, Inc.

Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions.  Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation.  The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

ADASUVE™ (Staccato loxapine) is Alexza's lead program, which is being developed for the acute treatment of agitation in adults with schizophrenia or bipolar disorder.  Alexza completed and announced positive results from both of its Phase 3 clinical trials and initially submitted the ADASUVE NDA in December 2009.  In October 2010, the Company received a Complete Response Letter from the FDA regarding the application.  The Company completed an end-of-review meeting with the FDA in December 2010 and a Risk Evaluation and Mitigation Strategy (REMS) guidance meeting with the FDA in April 2011.  The ADASUVE NDA was resubmitted on August 4, 2011 and has a Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.  The ADASUVE NDA will be presented to an advisory committee on December 12, 2011.

In October 2011, the Company established a commercial partnership for ADASUVE with Grupo Ferrer International, S.A.  Grupo Ferrer is a leading pharmaceutical company in Europe with extensive operations in the Americas, and is Alexza's partner in the commercialization of ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.  Alexza filed its ADASUVE Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in October 2011.  

For more information about Alexza, the Staccato system technology or the Company's development programs, please visit

Safe Harbor Statement

This press release includes forward-looking statements regarding the development, therapeutic potential, efficacy and safety of ADASUVE (Staccato loxapine). Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company's capital to support the Company's operations, the potential of the Company's ADASUVE NDA resubmission to adequately address the issues in the Complete Response Letter, the timing of the FDA's review of the NDA, the eventual prospects that ADASUVE will be approved for marketing in the U.S., and the timing and prospects for regulatory approval to market ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
(Date:11/30/2015)... Fla. , Nov. 30, 2015   The ... (the Institute) announced today that it has finalized a ... start-up company with technology developed at Florida State University. ... research, and bridges early funding gaps for companies spinning ... research institutions. --> ...
(Date:11/30/2015)... , November 30, 2015 /PRNewswire/ ... --> adds a ... for 2010 - 2015 with comprehensive ... a range of deal types, such ... strategic alliances. ...
(Date:11/30/2015)... -- --> --> According ... Product (Soft Tissue, All Tissue, Dental Welding Lasers), Application (Conservative ... - Global Forecast to 2020", published by MarketsandMarkets, is expected ... of 5.2% during the forecast period from 2015 to 2020. ... Figures spread through 167 P ages and in-depth TOC ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Tympani Inc., announced today that it ... Cisco. This designation recognizes Tympani as having fulfilled the training requirements and program ... the high-end enterprise contact center marketplace. , Ed Kapelinski, President of Tympani stated, ...
(Date:11/30/2015)... ... December 01, 2015 , ... The National Association of ... into its VIP Woman of the Year Circle. She is recognized with this ... exclusively for professional women, boasting 850,000 members and over 200 operating Local Chapters. ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... stressful. At the VA Maryland Health Care System, the Caregiver Support Program ... “Caregivers have a difficult job. Seventy-four percent report that their role as ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... dermatology, is proud to announce that its ThermiRFR temperature controlled radiofrequency platform has ... an innovative multi-application radiofrequency platform which uses temperature as a clinical endpoint. ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... fun atmosphere for Halloween festivities, the Word of Life Christian Church of Flint, ... game, and featuring a giant 1.25 ton pile of candy dubbed “Candy Mountain”. ...
Breaking Medicine News(10 mins):